ABL
Simon Joerger is currently working as a Technicien de bioproduction at ABL Europe since September 2022. Prior to this, Simon held the position of Manufacturing Associate II at Biogen from April 2021 to December 2021. Before that, Simon worked as a Technicien de fabrication at Octapharma Lingolsheim from June 2017 to April 2021, where Simon was responsible for various manufacturing operations following GMP standards. Simon also has experience as a Technicien de laboratoire at Eurofins Environnement France from June 2011 to June 2017, focusing on analyzing samples of soil, water, and air using chromatography techniques. Simon obtained a Diplôme universitaire de technologie (DUT) in Chimie from the University of Strasbourg in 2011.
ABL
From development to market ABL Europe provides GMP viral vectors, contributing to the success of our clients’ immunotherapy innovations. ABL Europe SAS is a pure-play GMP CMO licensed in accordance with EMA, completely dedicated to the provision of viral vector GMP contract manufacturing services, and a subsidiary of ABL Inc. under the corporate ownership of Institut Mérieux. ABL has a strong technical & regulatory track record in process development, scale-up & GMP manufacturing of filterable & non-sterile filterable (aseptic processing) viral vectors used in all phases of clinical development globally. With different adherent platforms (< 60 m2) and suspension (< 500 L) capabilities for drug substance and drug product (< 10,000 vials per batch) in-house, experience in process characterisation and validation, ABL provides its clients with a long-term strategic manufacturing option through clinical development & licensure for a range of virus vector gene therapy & vaccine products. ABL Europe’s clients are located worldwide.